Rhogam's Unconventional History And Why There Is No True Synthetic Replacement (Part 2 of 3)

By Ray Dogum, Chief Editor, Drug Discovery Online

This is part 2 of a 3-part editorial series on Rhogam and its road to eradicating Rh disease. In part 1, we cover Rh incompatibility and its significance in pregnancy and how Rhogam helped my family. Part 3 is on current global Rh disease eradication efforts and clinical lab supply limitations.

History of Rhogam

Rhogam is a polyclonal antibody biologic fractionated from donated human plasma containing high concentrations of anti-D. It was developed through a Columbia University and Ortho Pharmaceutical collaboration led by pathologist John Gorman, obstetrician Vincent Freda, and chemist William Pollack in the 1960s and approved by the FDA in 1968.

However, the contributing parties also included thousands of blood donors, some of whom generously committed to donating blood after sadly having multiple miscarriages resulting from hemolytic disease of the fetus and newborn (HDFN). They also included Sing Sing prison Rh-negative inmates, who volunteered to be injected with Rh-positive antigens to trigger their bodies to produce anti-D antibodies in the 1960s, and perhaps most daringly, John Gorman’s willing and pregnant sister-in-law, Kath Gorman, who was experimentally given the drug in England years before it was approved by the FDA.

The mechanism of Rh disease has been understood since the late 1930s, thanks to Vince Freda’s mentor, Alexander Wiener, who discovered that the Rh factor was a type of protein, or antigen, on the surface of red blood cells.

Mechanistically, Rhogam is an example of immunoprophylaxis: administering anti-D antibodies to an unsensitized Rh-negative pregnant person so that any Rh-positive fetal cells that enter maternal blood are opsonized and cleared before the mother mounts a durable endogenous anti-D response. Antibody opsonization is a process by which a pathogen is marked for phagocytosis through coating of a target cell with antibodies.

Why This Breakthrough Did Not Follow a Linear Drug Discovery Process

From a drug-discovery perspective, Rhogam is a big accomplishment despite its development not resembling the standard, linear R&D narrative.

There was no single molecular target to “drug.” The problem was a clinical phenotype (maternal sensitization to Rhesus antigens) emerging from population genetics, obstetric micro-bleeds, and adaptive immunity.

At one point in the early 1960s, Dr. Gorman read a general pathology textbook that turned out to be his eureka moment. It said, “The presence of circulating antibody, whether produced actively or received passively, depresses and may completely inhibit the immune response to the relevant antigen, although not to other antigens.” So, an excess of the passive antibody reduces an active immune response, possibly extinguishing the immune response altogether. This was a key turning point.

The solution was a biologic intervention built on a counterintuitive immunology insight: passive anti-D could prevent active anti-D.

Gorman and team spent years experimenting until they were able to prove, without a doubt, that their drug works safely and effectively, for the mother and the baby. It was a big deal back then, and it continues to be celebrated as one of medicine’s greatest achievements in history.

Attempts To Develop Non-Plasma-Derived Anti‑D

Despite more than 50 years of clinical success, Rho(D) immune globulin (RhIG) remains a plasma‑derived polyclonal antibody product, and a true synthetic replacement has not yet displaced it. Over the decades, multiple efforts have sought to develop recombinant or monoclonal anti‑D antibodies as scalable, pathogen‑independent alternatives to donor plasma.

These approaches are conceptually straightforward: instead of relying on a small pool of hyperimmunized human donors, defined antibodies could be manufactured consistently in cell culture. In practice, however, replicating the clinical performance of RhIG has proven far more difficult than anticipated, for reasons rooted in antibody biology rather than manufacturing constraints.

Why Synthetic Approaches Struggle

Polyclonality matters: RhIG is not a single molecule, but a heterogeneous mixture of antibodies targeting multiple Rh(D) epitopes. This diversity appears to enhance opsonization and clearance of fetal red blood cells across a range of biological contexts. In contrast, early monoclonal anti-D candidates—by definition epitope-restricted—often failed to achieve equivalent in vivo clearance, leading to inconsistent protection against sensitization.

A highly sensitive and poorly tractable mechanism: RhIG works through a finely balanced immunological mechanism. Passive antibodies promote rapid clearance of fetal red blood cells while simultaneously suppressing maternal alloimmunization. This mechanism is unusually sensitive to antibody properties, including affinity, epitope specificity, subclass, and fragment crystallizable (Fc) glycoform distribution. Small deviations can translate into measurable differences in clinical protection, making “functional equivalence” difficult to engineer.

Clinical and regulatory constraints amplified failures: Many monoclonal and recombinant anti‑D candidates entered clinical trials but failed to demonstrate non‑inferiority to plasma‑derived RhIG in early‑phase studies. Importantly, the benchmark is extremely high: established RhIG regimens reduce sensitization rates to well below 1%. Even small signals of reduced efficacy or variability have been sufficient to halt development in Western regulatory environments, where near‑perfect protection is expected.

Additionally, in a correspondence article in The Lancet, experts wrote, “Attempts to produce monoclonal RhIG and robustly establish therapeutic efficacy have been unsuccessful for various reasons, including insufficient funding for phase 3 trials. Moreover, the lack of mechanistic understanding of this type of immunoprophylaxis, the absence of an RhD animal model, and the observation that some monoclonal antibodies might even increase alloimmunisation risk have hampered the development of monoclonal RhIG.”

Limited Clinical Data on Monocloncal and Recombinant Anti-D

More recent programs have incorporated these lessons, focusing on Fc engineering, improved control of glycosylation, and in some cases combinations of antibodies to better mimic polyclonality. The most prominent example is trinbelimab, a recombinant anti‑D antibody developed by Bharat Serums & Vaccines and marketed in India as a “first recombinant anti‑Rh(D)” therapy.

Trinbelimab emerged from a long development lineage that began with a hybridoma-derived monoclonal anti-D called Rhoclone and progressed to recombinant expression systems. However, literature data for Rhoclone is limited to only two clinical trials of 110 women and 105 women receiving postpartum Rhoclone. So, it seems we really don’t know how well it works antenatally, an important distinction for Rh disease.

 In a randomized multicenter trial including 144 women, the recombinant anti-D, trinbelimab, demonstrated efficacy broadly comparable to plasma-derived products, with very low rates of transient sensitization and no persistent alloimmunization detected at six months.

However, even in this case, equivalence is not absolute, and the global evidence base remains limited. Trinbelimab and other similar products have not been adopted as standard of care in the US or EU, where regulatory expectations and evidentiary requirements are more stringent.

Infrastructure Barriers

As Dr. John Gorman and professor emeritus at Columbia University and former Worldwide Initiative for Rh disease Eradication (WIRhE) executive director, Dr. Steven Spitalnik, have emphasized to me, supply limitations are shaped as much by infrastructure, distribution, and clinical delivery systems as by manufacturing costs. This is especially true in low-and-middle-income countries where polyclonal anti-D supply is severely limited.

Even Dr. Gorman expressed doubts that a synthetic version would even make a difference in the actual problem, “Rhogam now costs about twenty-five dollars, and it could be one or two dollars with recombinant methods—but that’s not going to solve the problem,” he says.

The failure to fully replace plasma-derived anti-D is only one part of the access problem. Even if we somehow successfully develop a recombinant or monoclonal anti-D and reduce donor dependence, we would still depend on prenatal screening, reliable supply chains, clinician training, and timely administration. For biopharma, the lesson is humbling. Invention is not impact until the health systems can deliver it.